Obatoclax Mesylate (GX15-070)

Catalog No.S1057

Obatoclax Mesylate (GX15-070) Chemical Structure

Molecular Weight(MW): 413.49

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

9 Customer Reviews

  • In vivo antitumor efficacies of AZD2281 and GX15-070 alone or in combination in a BxPC-3 xenograft model. Tumor specimens were fixed in 10% formalin, embedded in paraffin, and cut into 4 lm-thick slides for H&E, PCNA, and CD34 staining.

    Cancer Lett 2014 348, 20-8. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    Gx15-070 induces autophagy and necroptosis in TET cells. Time-course electron microscopic morphology of T1682 cells treated with Gx15-070 at the indicated concentrations. After 1-h treatment, lamellar bodies (yellow arrow) consistent with early signs of autophagy and mitochondrial structural changes with loss of cristae (orange arrow) were evident. After 6-h treatment, early signs of necroptosis with intact nuclear envelope (top panel), and mitochondrial swelling with loss of mitochondrial matrix and cytoplasm vacuolization were observed (bottom panel). After 48-h treatment, late stages of necroptotic cell death (yellow arrow) and advanced stages of autophagy (orange arrow) were evident. The bottom panel depicts advanced stage of autophagic cell death with cytoplasmic vacuolization and lamellar bound structures consistent with autophagosomes.

    Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • ffect of Gx15-070 of mTOR pathway and on AMPKα. Effect of 6h Gx15-070 treatment on T1682 cells compared with untreated cells and cells starved for 6 h. The treatment induced a progressive reduction of p-AKT (Ser473 and Thr308) and p-RPS6 with the exception of 500 nM concentration. Progressive increase of LC3B-II and AMPKα phosphorylation was observed in Gx15-070 concentration-dependent manner.

    Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

     

    Upregulation of A1 is crucial for resistance to ABT-737. The role of different anti-apoptotic Bcl-2 factors in determining resistance to ABT-737 was investigated, comparing the pro-apoptotic effect of ABT-737, antimycin A and obatoclax on activated (filled circles) and non-activated (open circles) BM3.3 CD8 T cells. T-cell activation induced resistance to ABT-737 and to antimycin A, but not to obatoclax, demonstrating a crucial role of A1 in this phenomenon. Percentage of cells treated with DMSO-containing vehicle is given. Half maximal inhibitory concentration (IC50) and 95% confidence interval (95% CI) are reported in the table.

    Cell Death Dis 2012 3, e299. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • HUH6 cells (C-H) were incubated with and without 10 ng/ml TNF-α and obatoclax at 0.1, 0.3 uM. Fewer mitochondria with an intact membrane potential were observed in JC-1 staining when obatoclax and TNF-α were added to the culture. Reddish points indicate the aggregation of JC-1 in intact mitochondria, and missing of reddish points indicate the start of apoptosis.

    Exp Cell Res 2014 322, 217-25. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    Cell proliferation assays were carried out in SET-2 cells treated with increasing concentrations of NVP-BSK805 (empty triangles/solid line), obatoclax (filled squares/dotted line) or NVP-BSK805 in combination with a fixed obatoclax concentration of 700 nM (filled triangles/stippled line) for 72 hours.

     

     

    BMC Cancer 2011 11, 24. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • MEF cells were treated for  24 hours with the Bcl-2 antagonists  Obatoclax Mesylate at the indicated doses.Acute survival was monitored by replacing the drug-containing media with normal media and incubating the cells until visible colonies formed.Clonogenic survival is expressed relative to the numbers of colonies formed following 24 hours incubation in normal media(lacking drugs).

     

     

    Dr. Christine Hawkins of La Trobe University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    MDB-MA-231 cells were exposed to 30 μM cisplatin in the absence or in thepresence of 1 μM Obatoclax Mesylate .The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • Obataclax triggers cell death similarly in parental and ABT-737-resistant cells. Parental and ABT-R cells were treated with obataclax (Nalm-6 and Nalm-6 ABT-R: 10 uM; Reh and Reh ABT-R: 5 uM) for 18 h. (A) Cell viability was determined by trypan blue exclusion assay. (B) Mcl-1, NOXA, Bim, and b-actin as a loading control were analyzed by immunoblot. 

    Obatoclax Mesylate (GX15-070) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.
Features Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
Targets
Bcl-2 [1]
(Cell-free assay)
0.22 μM(Ki)
In vitro

Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. [1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. [2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KARPAS-45 MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvmTWM2OD1yLkCwNFA{OTdizszN NVLpd3NkW0GQR1XS
SK-MEL-30 NH\2bZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwMECwN|U2KM7:TR?= NVu0XG9TW0GQR1XS
NALM-6 NInsPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XuPGlEPTB;MD6wNFA{PTZizszN NFHFSXBUSU6JRWK=
KYSE-450 NEG5b4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi2NGdbUUN3ME2wMlAxODR4OTFOwG0> NVLtZVl5W0GQR1XS
BHY NIfFRZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nacmlEPTB;MD6wNFA3ODFizszN NVO5dXhiW0GQR1XS
GR-ST MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XFdGlEPTB;MD6wNFA3PDhizszN NITYeFFUSU6JRWK=
786-0 M4\lR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwMECwO|c3KM7:TR?= NWXae5ZwW0GQR1XS
C-33-A MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMECwPFQ5KM7:TR?= NFW1ZXZUSU6JRWK=
BHT-101 MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HrfWlEPTB;MD6wNFExPiEQvF2= MXLTRW5ITVJ?
EB2 M1LEdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV6xS2lxUUN3ME2wMlAxOTF6IN88US=> M3;OU3NCVkeHUh?=
G-361 MorES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLzeIJKSzVyPUCuNFAyOjRizszN MXnTRW5ITVJ?
KE-37 NGr6ZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\hTWM2OD1yLkCwNVI5KM7:TR?= M4DmZXNCVkeHUh?=
MHH-PREB-1 MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PlWGlEPTB;MD6wNFE1KM7:TR?= MlrBV2FPT0WU
MCF7 NXXKToVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDCeVFuUUN3ME2wMlAxOTV7IN88US=> NVLCOnRGW0GQR1XS
LOUCY NYmwSVZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMECxO|Uh|ryP NXLaNHliW0GQR1XS
EW-7 M3\jOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTUTWM2OD1yLkCwNVc2KM7:TR?= NXTJS3NZW0GQR1XS
KYSE-510 NGPOUZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMECyN|Mh|ryP NVjSS2Q5W0GQR1XS
SK-MEL-3 M4XYeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fPOmlEPTB;MD6wNFI3PCEQvF2= MX;TRW5ITVJ?
HAL-01 NELKbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1f5WWlEPTB;MD6wNFI6PyEQvF2= NECwXI5USU6JRWK=
HCC2998 MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMECzN|Uh|ryP NFe3SGZUSU6JRWK=
A375 M{fSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFO3cZBKSzVyPUCuNFA{PSEQvF2= M4HxSHNCVkeHUh?=
MZ7-mel MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[wTWM2OD1yLkCwN|k6KM7:TR?= NXXUUmlDW0GQR1XS
SH-4 NHvicYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMEC0NVch|ryP M3fodXNCVkeHUh?=
HT-144 NYLtSml6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMEC0N{DPxE1? MnGxV2FPT0WU
KYSE-140 MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMEC0N|Uh|ryP MlPmV2FPT0WU
PSN1 NY\zNZdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHvN3ZKSzVyPUCuNFA1PjdizszN NGnKcVJUSU6JRWK=
COLO-679 Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TxSmlEPTB;MD6wNFQ6QCEQvF2= MnqzV2FPT0WU
SW620 MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfLe4wxUUN3ME2wMlAxPTFzIN88US=> NHPZRXRUSU6JRWK=
HGC-27 M3\0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\JOWlJUUN3ME2wMlAxPTJ2IN88US=> NF3nXmVUSU6JRWK=
IGROV-1 NXPDXpNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGKyV4ZKSzVyPUCuNFA3KM7:TR?= NFLlRZFUSU6JRWK=
IGR-1 NWS4e25QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4e2cWlEPTB;MD6wNFYxOSEQvF2= NEfuc|lUSU6JRWK=
EW-1 MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nUSGlEPTB;MD6wNFY2OSEQvF2= MUXTRW5ITVJ?
769-P M4TrdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln6TWM2OD1yLkCwOlc5KM7:TR?= MoTkV2FPT0WU
HN MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;hWWlEPTB;MD6wNFY4QSEQvF2= NVXOflg6W0GQR1XS
SIG-M5 MmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TGO2lEPTB;MD6wNFcyKM7:TR?= Mo\CV2FPT0WU
IST-MEL1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XnXWlEPTB;MD6wNFgyQCEQvF2= Mk\JV2FPT0WU
ST486 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXO1W3NRUUN3ME2wMlAxQDJ3IN88US=> MWHTRW5ITVJ?
ES7 Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q4UGlEPTB;MD6wNFg1PiEQvF2= MVzTRW5ITVJ?
GAK MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlexTWM2OD1yLkCwPFQ5KM7:TR?= M1;CPHNCVkeHUh?=
BB30-HNC M1P3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwMEC4OVgh|ryP MlTSV2FPT0WU
IPC-298 M2\1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrCT25KSzVyPUCuNFA6OjdizszN NFy0[lZUSU6JRWK=
NKM-1 M3HQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwMEC5O|Ih|ryP M2S2W3NCVkeHUh?=
RKO NYDMW|l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXGOZJKSzVyPUCuNFExPDRizszN MUXTRW5ITVJ?
ACN MomzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTaTWM2OD1yLkCxNVMyKM7:TR?= M1vTT3NCVkeHUh?=
SW1417 MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vsSGlEPTB;MD6wNVIzPSEQvF2= NV\sbGlCW0GQR1XS
SR NFzNb4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPFTWM2OD1yLkCxNlM2KM7:TR?= MoLJV2FPT0WU
SNG-M M2rtbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMEGzNVch|ryP MkL2V2FPT0WU
CAL-12T M3;FfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\2[INKSzVyPUCuNFE{PDZizszN M12xO3NCVkeHUh?=
HSC-3 NGHQWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LVNGlEPTB;MD6wNVM2PSEQvF2= NHfRdYFUSU6JRWK=
DOHH-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlKyTWM2OD1yLkCxOFEzKM7:TR?= M32wXHNCVkeHUh?=
NB69 M37kW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljpTWM2OD1yLkCxOVY2KM7:TR?= M{LDSXNCVkeHUh?=
LC-2-ad MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEmyO25KSzVyPUCuNFE2QDFizszN MlnKV2FPT0WU
RVH-421 NUP4bmxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vPTmlEPTB;MD6wNVY4PCEQvF2= M2WyXHNCVkeHUh?=
TGW MlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwMEG3N|kh|ryP NFTsTVRUSU6JRWK=
HCC1569 NIO1W5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XMT2lEPTB;MD6wNVc6PyEQvF2= MYfTRW5ITVJ?
CAL-85-1 M3LQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTTS4JKSzVyPUCuNFE5OzJizszN M3TYXHNCVkeHUh?=
RPMI-8402 NW\kRmN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMEG4OVgh|ryP M2HlZnNCVkeHUh?=
THP-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn6SWtKSzVyPUCuNFE6QThizszN NFK3[GtUSU6JRWK=
ONS-76 NWrDUmFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMEKwN|Yh|ryP NI\NUG1USU6JRWK=
A2780 NXLDd45FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwMEKwO|kh|ryP Mm\QV2FPT0WU
RPMI-2650 M1S1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\pNYlTUUN3ME2wMlAzOjl4IN88US=> NFjCO|JUSU6JRWK=
MEL-HO MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnFXW1nUUN3ME2wMlAzOzR6IN88US=> NULFdZZGW0GQR1XS
MC-CAR NVLjOm85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[z[2lEPTB;MD6wNlM2PiEQvF2= NILpUW9USU6JRWK=
HSC-2 M3rXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMEK0OlYh|ryP MnjhV2FPT0WU
MEL-JUSO Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v2RmlEPTB;MD6wNlQ4OyEQvF2= MonXV2FPT0WU
CAL-62 M4O3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LuTGlEPTB;MD6wNlYxOiEQvF2= MnfuV2FPT0WU
DMS-273 MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfGW|h2UUN3ME2wMlAzQDR5IN88US=> MlPGV2FPT0WU
S-117 NUGyVFhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M12wUWlEPTB;MD6wNlkxPiEQvF2= M3;D[3NCVkeHUh?=
SUP-T1 NHfWcXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS4cHBsUUN3ME2wMlAzQTR7IN88US=> MlLzV2FPT0WU
MZ2-MEL M{jCRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrS[nFrUUN3ME2wMlAzQTV7IN88US=> M{TMUHNCVkeHUh?=
KYSE-270 NFTsU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:zSI1KSzVyPUCuNFI6PzZizszN NUT4R2NpW0GQR1XS
CMK MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrnTWM2OD1yLkCzNFI{KM7:TR?= MkTNV2FPT0WU
8505C NV;HdmdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvUTWM2OD1yLkCzNFQh|ryP NFHQXoNUSU6JRWK=
NUGC-3 M1zFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwMEOwOFgh|ryP NYewPGFmW0GQR1XS
A101D M1fiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXDO|B4UUN3ME2wMlA{ODV3IN88US=> MYLTRW5ITVJ?
G-401 M2XP[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMEOwPVMh|ryP M17YNHNCVkeHUh?=
OVCAR-8 NXnLXI9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDlTWM2OD1yLkCzNVA4KM7:TR?= MWDTRW5ITVJ?
IMR-5 MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL6PVJKSzVyPUCuNFMzPDRizszN Mmn1V2FPT0WU
DoTc2-4510 NGnJfGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzQ[3RKSzVyPUCuNFM{QTNizszN NFvzPGxUSU6JRWK=
HOS MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDMfXptUUN3ME2wMlA{PDd|IN88US=> M2rldXNCVkeHUh?=
HEC-1 NUfwWnJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlH2TWM2OD1yLkCzOlgh|ryP MVzTRW5ITVJ?
SW756 M123Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2noeWlEPTB;MD6wN|gzOSEQvF2= M2HoRnNCVkeHUh?=
NCI-H64 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPFR4NKSzVyPUCuNFM5PDJizszN NGTwd2xUSU6JRWK=
EW-16 NEjORY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDN[Ip5UUN3ME2wMlA{QTB7IN88US=> Mly2V2FPT0WU
CAL-51 MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j1bmlEPTB;MD6wOFAxPSEQvF2= MV3TRW5ITVJ?
KYSE-150 M2X5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjOUohPUUN3ME2wMlA1ODFzIN88US=> NVy2dGFFW0GQR1XS
SW1710 NF7vSo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK0foFKSzVyPUCuNFQxOThizszN NYP6dohkW0GQR1XS
HuP-T4 Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMESxNVgh|ryP NWf2SFVUW0GQR1XS
LB373-MEL-D MoDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHjT5pKSzVyPUCuNFQzOzJizszN NX;YbY9lW0GQR1XS
EW-13 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\5V2lEPTB;MD6wOFQxPiEQvF2= MX;TRW5ITVJ?
HT-29 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwMES0PUDPxE1? NYrrS3Z4W0GQR1XS
SCC-25 MnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTKUXRKSzVyPUCuNFQ1QTRizszN NYrUZ2t6W0GQR1XS
REH NHTkS|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XlTWlEPTB;MD6wOFY{PSEQvF2= Ml63V2FPT0WU
L-363 NX;RN3UyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D2UGlEPTB;MD6wOFY4QSEQvF2= NYezNXd1W0GQR1XS
NCI-H1770 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmj4TWM2OD1yLkC0Olk4KM7:TR?= MoPlV2FPT0WU
CHL-1 NETXeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHtSJBKSzVyPUCuNFQ5PTdizszN MmDQV2FPT0WU
ES1 M4r5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMES4PFUh|ryP NFOzfIlUSU6JRWK=
SCC-15 M{n0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzmTWM2OD1yLkC0PVAzKM7:TR?= Ml3MV2FPT0WU
MRK-nu-1 M{HIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrrWWg4UUN3ME2wMlA1QTN4IN88US=> NEL0c3RUSU6JRWK=
PF-382 NWfSbZBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHXTIxKSzVyPUCuNFQ6OzlizszN NULoW3FVW0GQR1XS
COLO-680N MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwMEWwOFch|ryP MUHTRW5ITVJ?
LK-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DI[2lEPTB;MD6wOVA3OyEQvF2= M2XH[XNCVkeHUh?=
NCI-H2342 MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7RZnMyUUN3ME2wMlA2OTF5IN88US=> M2n1[HNCVkeHUh?=
HMV-II NIn2SFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEG0XVNKSzVyPUCuNFUzOzlizszN NH[0WYJUSU6JRWK=
PC-14 M4HQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMEWyOVIh|ryP M1ywSnNCVkeHUh?=
COLO-320-HSR NU\yOpNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf4TWM2OD1yLkC1Nlg6KM7:TR?= M13GeHNCVkeHUh?=
697 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDRcWlKSzVyPUCuNFU{OjNizszN MY\TRW5ITVJ?
NEC8 NWTGfIlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMEW1PUDPxE1? NGi0OVdUSU6JRWK=
LCLC-97TM1 MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHOTWM2OD1yLkC1OVk1KM7:TR?= M3niT3NCVkeHUh?=
Daoy NGS1T2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojQTWM2OD1yLkC1OlE3KM7:TR?= M{j3T3NCVkeHUh?=
ETK-1 NUjmb5p7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LSO2lEPTB;MD6wOVY4OiEQvF2= NGjKdnhUSU6JRWK=
A388 MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4OyVGlEPTB;MD6wOVY6PSEQvF2= Mn;qV2FPT0WU
COLO-205 M{Did2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf2[XBsUUN3ME2wMlA2PzF4IN88US=> M{LrWnNCVkeHUh?=
SK-PN-DW MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwMEW3Nlkh|ryP M{e1OnNCVkeHUh?=
SF268 NVTxO5RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwMEW3OVYh|ryP NUm1VYJtW0GQR1XS
OCI-AML2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkOzTWM2OD1yLkC1O|c4KM7:TR?= M3rZdHNCVkeHUh?=
GAMG MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu1enRMUUN3ME2wMlA2QCEQvF2= M2nZbHNCVkeHUh?=
BCPAP MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojDTWM2OD1yLkC1PFkzKM7:TR?= MluwV2FPT0WU
BC-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnSR|ZsUUN3ME2wMlA3ODJ{IN88US=> M{H1UnNCVkeHUh?=
IA-LM NXrOUWNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlKzTWM2OD1yLkC2NFU{KM7:TR?= M1zXb3NCVkeHUh?=
NCI-H1299 NYHETFl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHmepZDUUN3ME2wMlA3OTNizszN NVjONY5QW0GQR1XS
COR-L23 NFTFXnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXtTWM2OD1yLkC2NVM1KM7:TR?= Mk\rV2FPT0WU
KYSE-180 NUf2fHpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXsTWM2OD1yLkC2NVQzKM7:TR?= MXvTRW5ITVJ?
LOXIMVI MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnT1TWM2OD1yLkC2NVg5KM7:TR?= MofnV2FPT0WU
BL-41 NH[wdJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTDfZZVUUN3ME2wMlA3OjF7IN88US=> MYjTRW5ITVJ?
BL-70 M{PqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHONoZ2UUN3ME2wMlA3OzB{IN88US=> MmC0V2FPT0WU
NOS-1 NUXFUlhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfaeHd6UUN3ME2wMlA3PDFzIN88US=> MlXBV2FPT0WU
NB13 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwME[0NlEh|ryP MXvTRW5ITVJ?
CAL-27 NFjpV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwME[0OlQh|ryP NWrVcpBmW0GQR1XS
CA46 NHXReHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne3TWM2OD1yLkC2OVM4KM7:TR?= MYXTRW5ITVJ?
SW962 MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwME[1Olkh|ryP NV;5fIM1W0GQR1XS
NCI-H226 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjYTWM2OD1yLkC2OlMzKM7:TR?= M2L6VHNCVkeHUh?=
KYSE-70 NHnROoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33LbWlEPTB;MD6wOlk1PSEQvF2= MYjTRW5ITVJ?
Daudi NYjOfWZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3TO4o2UUN3ME2wMlA4ODhzIN88US=> MVnTRW5ITVJ?
SW626 NEf1SoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMEeyNFQh|ryP MV3TRW5ITVJ?
ESS-1 NUPsNpduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnH1TWM2OD1yLkC3NlQ3KM7:TR?= M1e3Z3NCVkeHUh?=
YT NHPre|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMEezOFUh|ryP NH2zfZZUSU6JRWK=
P12-ICHIKAWA NFrzSohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITFSGxKSzVyPUCuNFc{PDlizszN MnyxV2FPT0WU
BxPC-3 Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[2Wo8{UUN3ME2wMlA4PDV6IN88US=> NHHvU5pUSU6JRWK=
CTV-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7uTWM2OD1yLkC3OVE4KM7:TR?= NE\UPIVUSU6JRWK=
MLMA M{XsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLseWJKSzVyPUCuNFc2OzRizszN MWLTRW5ITVJ?
WSU-NHL NVfjUmdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPvTWM2OD1yLkC3OVU1KM7:TR?= MVPTRW5ITVJ?
CTB-1 NWGz[FJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMEe1PFgh|ryP MVjTRW5ITVJ?
MMAC-SF Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PDV2lEPTB;MD6wO|Y3QCEQvF2= MXvTRW5ITVJ?
8-MG-BA MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwMEe4NFEh|ryP MXvTRW5ITVJ?
NCI-H358 M3TBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzadZRJUUN3ME2wMlA4QDd7IN88US=> MnrBV2FPT0WU
BFTC-905 M364[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnjTWM2OD1yLkC3PVA6KM7:TR?= M37tNXNCVkeHUh?=
NCI-H727 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnGZWRKSzVyPUCuNFgxPTNizszN M4r4NXNCVkeHUh?=
CHP-212 MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXLbpJjUUN3ME2wMlA5ODl3IN88US=> NVu2cY1wW0GQR1XS
HOP-62 M2\URmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTwVpRpUUN3ME2wMlA5OjR3IN88US=> M3rqUnNCVkeHUh?=
CESS M{Tae2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TYe2lEPTB;MD6wPFI3QSEQvF2= NEfqZmFUSU6JRWK=
HuCCT1 M4\abmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXNUphKSzVyPUCuNFg{OzNizszN Mmm4V2FPT0WU
DEL MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjBdHlKSzVyPUCuNFg{PDdizszN NEK4fmJUSU6JRWK=
5637 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{O2Z2lEPTB;MD6wPFM3PyEQvF2= MWXTRW5ITVJ?
RS4-11 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnrTpZKSzVyPUCuNFg1QTdizszN M36xeXNCVkeHUh?=
KURAMOCHI NWfuXVVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHjTWM2OD1yLkC4OVA6KM7:TR?= NEeyV2RUSU6JRWK=
A427 M2Pn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwMEi1NVIh|ryP MWfTRW5ITVJ?
A3-KAW M3rMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvGWYlKSzVyPUCuNFg2PjZizszN NH\u[mhUSU6JRWK=
LS-123 MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[4TllKSzVyPUCuNFg4OTlizszN NECxc3VUSU6JRWK=
LoVo M4XkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFX5XnpKSzVyPUCuNFg4OiEQvF2= MnO1V2FPT0WU
PA-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\vTWM2OD1yLkC4O|Y6KM7:TR?= Mm\BV2FPT0WU
CP50-MEL-B Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S4NWlEPTB;MD6wPFc6OyEQvF2= MYjTRW5ITVJ?
A431 M1XydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFz2NZRKSzVyPUCuNFg5ODFizszN NGHYTZNUSU6JRWK=
HCT-116 NEOyXGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\CelFKSzVyPUCuNFg5ODJizszN M2fySnNCVkeHUh?=
A4-Fuk MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fHZ2lEPTB;MD6wPFk1PyEQvF2= NHj1bG1USU6JRWK=
RPMI-6666 M{LRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMEi5Olch|ryP M162SnNCVkeHUh?=
Calu-6 NUjKUIQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2mydmlEPTB;MD6wPVAzQSEQvF2= NVnYfZcxW0GQR1XS
KMOE-2 NVTsUWoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGG4XItKSzVyPUCuNFkxOzlizszN Mle5V2FPT0WU
A704 M3nGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvoTWM2OD1yLkC5NVUh|ryP NIfXZopUSU6JRWK=
HO-1-N-1 NELo[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfBT3RPUUN3ME2wMlA6OjR7IN88US=> NXLjOopRW0GQR1XS
NCI-H2122 NYfrZ4FJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMEmzO|gh|ryP Mm\JV2FPT0WU
U-698-M MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2KzZ2lEPTB;MD6wPVQxQSEQvF2= NEjzO3FUSU6JRWK=
IST-SL2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrZXXJNUUN3ME2wMlA6PDZ6IN88US=> M3LLZXNCVkeHUh?=
TE-10 Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHPfVdKSzVyPUCuNFk2QDRizszN M1f2XHNCVkeHUh?=
PANC-03-27 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jZdmlEPTB;MD6wPVY4OSEQvF2= MX\TRW5ITVJ?
KYSE-410 NH3xfW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHqTWM2OD1yLkC5O|k4KM7:TR?= MkXWV2FPT0WU
TE-8 M2[5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMEm4PFUh|ryP M1vWcHNCVkeHUh?=
MN-60 M3ntVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwMEm4PVch|ryP MYHTRW5ITVJ?
NCI-H460 NVm5cpo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O1TGlEPTB;MD6xNFA6KM7:TR?= M1jIfnNCVkeHUh?=
LB771-HNC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHMTWM2OD1yLkGwNlU2KM7:TR?= M3XycnNCVkeHUh?=
ES4 MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMUCyOlQh|ryP NELWWG9USU6JRWK=
HUTU-80 NHrUcopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXOTWM2OD1yLkGwN|Y2KM7:TR?= M2LnenNCVkeHUh?=
647-V NFrBbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwMUC0NFgh|ryP NXnnNHI4W0GQR1XS
HTC-C3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXDTWxKSzVyPUCuNVA1OzJizszN NXPXUGdSW0GQR1XS
NTERA-S-cl-D1 NUXJTGpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrETWM2OD1yLkGwOFQ5KM7:TR?= MVXTRW5ITVJ?
A2058 M4rNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwMUC2OVUh|ryP M3fUWHNCVkeHUh?=
MZ1-PC NH7aZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLHTWM2OD1yLkGwPFMh|ryP MUnTRW5ITVJ?
J82 MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkWzTWM2OD1yLkGwPFg1KM7:TR?= MnjtV2FPT0WU
ARH-77 NVO1XnRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jubWlEPTB;MD6xNUDPxE1? M3;ndnNCVkeHUh?=
Ca9-22 NUPBSYNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYH6SFNRUUN3ME2wMlEyOTJ6IN88US=> MUjTRW5ITVJ?
NCI-H1648 NYPNRVVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\ud2hDUUN3ME2wMlEyOjh4IN88US=> M2nQOXNCVkeHUh?=
MC116 MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwMUGzN|ch|ryP M2jHSnNCVkeHUh?=
EoL-1-cell M4jXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[yV2lEPTB;MD6xNVQ3PyEQvF2= MlXVV2FPT0WU
PANC-10-05 NFXV[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFi0RmtKSzVyPUCuNVE1QTFizszN MXzTRW5ITVJ?
SF539 M1jaOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;rTWM2OD1yLkGxOlE3KM7:TR?= MXzTRW5ITVJ?
ES8 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3TXFBKSzVyPUCuNVE3OzNizszN NH;ROGlUSU6JRWK=
NCI-H810 MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL5R|ZKSzVyPUCuNVE3PjRizszN NI\2O2RUSU6JRWK=
J-RT3-T3-5 NUnXR4hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwMUG3OUDPxE1? M3nmZ3NCVkeHUh?=
NY NWnEUIdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwMUG4NVch|ryP MXnTRW5ITVJ?
NCI-SNU-1 M1:wV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\WfWlEPTB;MD6xNlE1QCEQvF2= NIDNXlVUSU6JRWK=
EFM-19 NGLOTVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvSdFFmUUN3ME2wMlEzOzd2IN88US=> NFq4bolUSU6JRWK=
HCC1806 M3zSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILLR|dKSzVyPUCuNVI{QDNizszN NGrtUotUSU6JRWK=
HCE-T NV\me|RjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[5ZWlEPTB;MD6xNlU{OSEQvF2= NEjHbHJUSU6JRWK=
HT-1376 NWW1dFRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTUTWM2OD1yLkGyOlY5KM7:TR?= MmP6V2FPT0WU
BE-13 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfJbHdpUUN3ME2wMlEzQDZ4IN88US=> MluyV2FPT0WU
NCI-H520 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\TOJlKSzVyPUCuNVI5PjdizszN M2nPe3NCVkeHUh?=
SK-MES-1 NI\vPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr4T21KSzVyPUCuNVI6OTNizszN MWfTRW5ITVJ?
SNU-423 M1jBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:1UpBKSzVyPUCuNVI6OTRizszN M2XFenNCVkeHUh?=
Ramos-2G6-4C10 M1W4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHu2dIxKSzVyPUCuNVI6OTZizszN NFz1NFJUSU6JRWK=
EW-18 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfFTWM2OD1yLkGzNFI3KM7:TR?= MWfTRW5ITVJ?
NCI-H2087 NH\1T3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[zTWM2OD1yLkGzNFI4KM7:TR?= NILq[pNUSU6JRWK=
COLO-792 NYHqbVRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HYbmlEPTB;MD6xN|E3PSEQvF2= NHn1bI5USU6JRWK=
QIMR-WIL NXTW[HllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fnb2lEPTB;MD6xN|IzOyEQvF2= M1znb3NCVkeHUh?=
ACHN NU\jSnUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHubpIyUUN3ME2wMlE{OjR5IN88US=> NFL2[VdUSU6JRWK=
RPMI-8866 M1mwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfkTWM2OD1yLkGzNlYyKM7:TR?= MYDTRW5ITVJ?
SK-LU-1 NXLwR|J3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPKfJE4UUN3ME2wMlE{PDR7IN88US=> NVXVdZhsW0GQR1XS
SK-UT-1 NF30c5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX0emNIUUN3ME2wMlE{PjJ6IN88US=> MkX6V2FPT0WU
MFE-296 NYe5O4JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ny[mlEPTB;MD6xN|g3PCEQvF2= MnPGV2FPT0WU
RD NV3tSoxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjhVG5QUUN3ME2wMlE{QTl5IN88US=> NIfyZYZUSU6JRWK=
LS-411N MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\sfHV4UUN3ME2wMlE1Ojl3IN88US=> Ml7EV2FPT0WU
NCI-H747 MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33RUmlEPTB;MD6xOFMh|ryP NELudJpUSU6JRWK=
ES6 NVLYN3lrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvHcG5KSzVyPUCuNVQ{PiEQvF2= NYLFTZl7W0GQR1XS
TE-1 NFzGPI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDRSGVKSzVyPUCuNVQ1ODdizszN NWjQV4FJW0GQR1XS
SJSA-1 NX\Yb2o1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwMUS3NFch|ryP MVzTRW5ITVJ?
NCI-H1355 M2HDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHzTWM2OD1yLkG1Nlk{KM7:TR?= NFX6bGNUSU6JRWK=
HEL NUK5b2JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXWfVZ1UUN3ME2wMlE2PDR5IN88US=> M2T1PXNCVkeHUh?=
639-V MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED1ZZlKSzVyPUCuNVU2QTZizszN MknSV2FPT0WU
AN3-CA MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3q0NWlEPTB;MD6xOVY{QSEQvF2= NYPwTHpEW0GQR1XS
SK-MEL-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlyxTWM2OD1yLkG1OlY5KM7:TR?= NWHpflI{W0GQR1XS
SW872 MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXm3TZh3UUN3ME2wMlE3ODR{IN88US=> NX[5b2dWW0GQR1XS
DU-4475 M2\oXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXOO49EUUN3ME2wMlE3OTZ{IN88US=> M3q3cXNCVkeHUh?=
YKG-1 NF:2XHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7hepZKSzVyPUCuNVYzPzNizszN NIXMVZFUSU6JRWK=
GT3TKB M170PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjiO4JSUUN3ME2wMlE3Ojh|IN88US=> MXLTRW5ITVJ?
GB-1 NWTKbYdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\ETWM2OD1yLkG2OFI1KM7:TR?= Mo\QV2FPT0WU
KARPAS-422 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITUe3ZKSzVyPUCuNVY2PzRizszN NU\W[ZFyW0GQR1XS
ATN-1 M3G1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknjTWM2OD1yLkG2OlU3KM7:TR?= M2P2ZnNCVkeHUh?=
HLE NUTFPIV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlT5TWM2OD1yLkG2PFc4KM7:TR?= M1[2c3NCVkeHUh?=
D-542MG Mm\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHzc|gzUUN3ME2wMlE3QTh4IN88US=> MX3TRW5ITVJ?
EB-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlftTWM2OD1yLkG3N|Eh|ryP Moq1V2FPT0WU
HCC1143 MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwMUezPVYh|ryP M{TkfXNCVkeHUh?=
DJM-1 NFHicJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwMUe0OVEh|ryP Ml25V2FPT0WU
BT-474 NI\mSWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HxcWlEPTB;MD6xO|Q5QSEQvF2= MonCV2FPT0WU
BB65-RCC NXHybXVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMUe1OFUh|ryP NUP5S2p1W0GQR1XS
NCI-H292 NYCyUmpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\2T3EyUUN3ME2wMlE4PjBzIN88US=> MnO2V2FPT0WU
MKN28 NF;mPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D0SGlEPTB;MD6xO|Y2OyEQvF2= M4XyZ3NCVkeHUh?=
TK10 NXWzdod4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV20OYt6UUN3ME2wMlE4PzB{IN88US=> NXXZXYF[W0GQR1XS
TYK-nu NUPwWpF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMUe5OFkh|ryP M3:ze3NCVkeHUh?=
8305C NWrDXo15T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXTeZdKSzVyPUCuNVc6PzFizszN NFPUNHpUSU6JRWK=
MV-4-11 NYDj[os{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrXTWM2OD1yLkG3PVc4KM7:TR?= Moi3V2FPT0WU
NCI-H522 NIDJUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknvTWM2OD1yLkG4NFk1KM7:TR?= NXfyPG83W0GQR1XS
Hs-578-T M1WwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vrVmlEPTB;MD6xPFI6OiEQvF2= NV7wS5l4W0GQR1XS
LCLC-103H NWDnUZBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vEZmlEPTB;MD6xPFUzPyEQvF2= MVPTRW5ITVJ?
MHH-ES-1 M{\Dfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LqZ2lEPTB;MD6xPFYzQSEQvF2= NGnNXlJUSU6JRWK=
NCI-H441 NVK3[ZhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwMUmxOFgh|ryP MX7TRW5ITVJ?
AM-38 MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTWXnpKSzVyPUCuNVkzOjVizszN M3PmW3NCVkeHUh?=
SW1783 Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvPNFZiUUN3ME2wMlE6OzB3IN88US=> M3;BRnNCVkeHUh?=
SK-HEP-1 Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnsS2tKSzVyPUCuNVk3OzdizszN MUjTRW5ITVJ?
OAW-28 MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwMkCxO|gh|ryP NFjVPW9USU6JRWK=
TE-15 M{Drb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTYTWM2OD1yLkKwNlUzKM7:TR?= NVWz[IFYW0GQR1XS
HCE-4 NYnQd2h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrYTWM2OD1yLkKwNlg1KM7:TR?= NFznO4JUSU6JRWK=
JiyoyeP-2003 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV30fYZqUUN3ME2wMlIxOzN4IN88US=> NUXXVFBtW0GQR1XS
OVCAR-4 NF\PRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vQdmlEPTB;MD6yNFYzQCEQvF2= M2HP[XNCVkeHUh?=
SNU-449 MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;aTWM2OD1yLkKwO|k4KM7:TR?= M3jseHNCVkeHUh?=
SBC-5 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2K2RmlEPTB;MD6yNVIyPSEQvF2= M1GzdnNCVkeHUh?=
T84 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXrSZFKSzVyPUCuNlEzPDhizszN NEPtUYhUSU6JRWK=
LP-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrxXnY2UUN3ME2wMlIyOzB{IN88US=> NXvTO5Y2W0GQR1XS
MG-63 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLGTWM2OD1yLkKxN|gzKM7:TR?= M3GyXnNCVkeHUh?=
OAW-42 MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX2yZY5zUUN3ME2wMlIyPDd6IN88US=> MXXTRW5ITVJ?
L-540 M3LJRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMkG1PVgh|ryP M4r3TnNCVkeHUh?=
RH-1 M1LCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz6TWM2OD1yLkKyNlQzKM7:TR?= Mn\RV2FPT0WU
HCT-15 MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XCW2lEPTB;MD6yNlQ5PCEQvF2= MXTTRW5ITVJ?
OCUB-M MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\mTWM2OD1yLkKyOFg5KM7:TR?= MofrV2FPT0WU
GP5d NIfkVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7BfllGUUN3ME2wMlIzPTJ6IN88US=> NUm3bmpFW0GQR1XS
NCI-H2030 Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm3TWM2OD1yLkKyO|M1KM7:TR?= NV3pelh2W0GQR1XS
ML-2 NWXxUXduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TveWlEPTB;MD6yNlg5QSEQvF2= MmfjV2FPT0WU
CAL-39 NYOzNoNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfvTWM2OD1yLkKyPVM3KM7:TR?= M2DOeHNCVkeHUh?=
MIA-PaCa-2 MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPBTWM2OD1yLkKzNlg4KM7:TR?= Mn:1V2FPT0WU
TE-9 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\4c2lEPTB;MD6yN|MzKM7:TR?= NFHrcnlUSU6JRWK=
LB2518-MEL MlLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXy0Z2FqUUN3ME2wMlI{Ozd{IN88US=> MW\TRW5ITVJ?
DB NUHw[4NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMkO0N|gh|ryP MVHTRW5ITVJ?
NCI-H596 NVHzWpNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV30OY1JUUN3ME2wMlI{PTdzIN88US=> M1T2bXNCVkeHUh?=
SW1990 NYPZVJRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXaTWM2OD1yLkKzPVQ3KM7:TR?= NWnLbW5JW0GQR1XS
P30-OHK M2nVUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEmxR3dKSzVyPUCuNlQxPSEQvF2= M3;ue3NCVkeHUh?=
ALL-PO NETlfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfBSmhjUUN3ME2wMlI1OTZ7IN88US=> Ml3vV2FPT0WU
Saos-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoniTWM2OD1yLkK0OVcyKM7:TR?= M2[zOXNCVkeHUh?=
MFH-ino NILDZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoSwTWM2OD1yLkK0OlkzKM7:TR?= NYDvSGZSW0GQR1XS
OE33 NVHQelhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2i0UWlEPTB;MD6yOVEyKM7:TR?= M{XOXHNCVkeHUh?=
Calu-3 NVTlcYQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvHXHJmUUN3ME2wMlI2Ojl5IN88US=> NF;kNGhUSU6JRWK=
HT NV\aU4tXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTud5JDUUN3ME2wMlI2PjJzIN88US=> NG[wWmZUSU6JRWK=
LXF-289 NWjQV2Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDyVndKSzVyPUCuNlU6QDRizszN MkfFV2FPT0WU
KGN NYPlNGF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHGT3lGUUN3ME2wMlI3ODh7IN88US=> M3nUOnNCVkeHUh?=
NCI-H1417 NYHT[GsxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMk[1NlQh|ryP MYXTRW5ITVJ?
SF126 NHG2[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HYd2lEPTB;MD6yO|MxOiEQvF2= MWfTRW5ITVJ?
SAS NF;ROplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoK0TWM2OD1yLkK3N|A5KM7:TR?= MXLTRW5ITVJ?
22RV1 NWfY[3NqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3pTWM2OD1yLkK3N|c5KM7:TR?= MWHTRW5ITVJ?
GI-1 MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzhbFRKSzVyPUCuNlc1QDdizszN NWDI[lNoW0GQR1XS
ES3 M{Pnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMke3OlMh|ryP NWLlZ|ZHW0GQR1XS
NB1 Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3ZTWM2OD1yLkK3PFc3KM7:TR?= NIrvdmZUSU6JRWK=
NCI-H650 M4HufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfvUYlKSzVyPUCuNlg{ODJizszN M4f3eHNCVkeHUh?=
IST-MES1 M4rPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnlNVZTUUN3ME2wMlI5PTV2IN88US=> NFzJVYdUSU6JRWK=
UM-UC-3 NVjHfJRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DJZWlEPTB;MD6yPVE1KM7:TR?= MUTTRW5ITVJ?
CAL-120 M2nKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L2[WlEPTB;MD6yPVY{OSEQvF2= MXPTRW5ITVJ?
UACC-62 NUf3ZnpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rxOmlEPTB;MD6zNFI1OSEQvF2= MlXoV2FPT0WU
TE-11 M161c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLTSZBKSzVyPUCuN|AzPDlizszN NF;JZY5USU6JRWK=
MKN1 NUT0NJhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwM{CzOkDPxE1? MmKxV2FPT0WU
KS-1 NVfOPYNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHVcGY4UUN3ME2wMlMxPTJ4IN88US=> M2HROnNCVkeHUh?=
GCIY M3nIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwM{GwNFIh|ryP NGTTVZRUSU6JRWK=
OVCAR-5 NEH5fGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwM{GxNFYh|ryP MoLOV2FPT0WU
U-266 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHhZmZKSzVyPUCuN|EyPDdizszN M2XGd3NCVkeHUh?=
Calu-1 MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nuNGlEPTB;MD6zNVI5QSEQvF2= MkG1V2FPT0WU
SK-LMS-1 NYWyW|U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwM{G0Nlkh|ryP MnfXV2FPT0WU
COLO-741 M1\tSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPkd|lRUUN3ME2wMlMyPjF2IN88US=> MYDTRW5ITVJ?
RPMI-8226 NWfZd2xmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PZTWlEPTB;MD6zNVY1OSEQvF2= NF3IWIxUSU6JRWK=
KM12 NU\pdFJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwM{G4N{DPxE1? MoLBV2FPT0WU
NMC-G1 M1rEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnjeJlHUUN3ME2wMlMyQDZizszN NXj6[WROW0GQR1XS
SJRH30 NX;HXoJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M32zNmlEPTB;MD6zNlA2OiEQvF2= MoDwV2FPT0WU
COR-L105 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwM{KyNVgh|ryP NVfIZ|I5W0GQR1XS
IM-9 NXi2XmZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPrb49EUUN3ME2wMlM{ODJzIN88US=> NIrGZYNUSU6JRWK=
TE-12 NWrMfW43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX4XFdOUUN3ME2wMlM{OzF5IN88US=> MWnTRW5ITVJ?
KG-1 M1nEPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjCS2VPUUN3ME2wMlM{PDN{IN88US=> NWLmcVN{W0GQR1XS
U251 NHHhXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnziTWM2OD1yLkOzOFU3KM7:TR?= MUTTRW5ITVJ?
EFO-27 M4HRR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvkZ5pKSzVyPUCuN|M6PTFizszN NYjRb4F{W0GQR1XS
EW-24 M13nOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fK[WlEPTB;MD6zN|k5PCEQvF2= MVHTRW5ITVJ?
SF295 NXL6boNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfXTWM2OD1yLkOzPVk6KM7:TR?= NXPnNXZnW0GQR1XS
MC-IXC NG\LSoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XVfWlEPTB;MD6zOFUh|ryP NHLTfVdUSU6JRWK=
NCI-H2405 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwM{S3N|Ih|ryP MnPUV2FPT0WU
NCI-H2009 MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\STWM2OD1yLkO0O|M6KM7:TR?= MX3TRW5ITVJ?
LB1047-RCC NVS4eYp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwM{W4NVUh|ryP Ml7LV2FPT0WU
KNS-81-FD Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwM{[2Olch|ryP NVLJSHdWW0GQR1XS
HOP-92 M1fjV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXy[FlKSzVyPUCuN|Y5OyEQvF2= Mn[zV2FPT0WU
L-428 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwM{ewNVYh|ryP MUTTRW5ITVJ?
C3A NYHXSWZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XVfmlEPTB;MD6zO|M4QSEQvF2= NYDCPGJEW0GQR1XS
NCI-H1792 MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy3c|JYUUN3ME2wMlM4PjV3IN88US=> MnHaV2FPT0WU
HuH-7 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHOyTIRKSzVyPUCuN|c6OSEQvF2= NFTNWoJUSU6JRWK=
AGS NVT5UnZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M135eGlEPTB;MD6zPFY{QCEQvF2= NIrxeVhUSU6JRWK=
HT-1197 M4j2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nrZWlEPTB;MD6zPVQ3KM7:TR?= NGDBco1USU6JRWK=
CGTH-W-1 M1vJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXUVWhKSzVyPUCuN|k6OTNizszN NF;HTnpUSU6JRWK=
KNS-42 MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[yTWM2OD1yLkSwNFQ2KM7:TR?= M1TOT3NCVkeHUh?=
HuO-3N1 NIfCUINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwNECwOVUh|ryP NXfnSWlVW0GQR1XS
VMRC-RCZ MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU[1eFZ{UUN3ME2wMlQxOzB|IN88US=> MknkV2FPT0WU
SW954 M33N[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLZTWM2OD1yLkSwN|M2KM7:TR?= M2LhSnNCVkeHUh?=
MES-SA MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4O5U2lEPTB;MD60NFUxPSEQvF2= NFTEO49USU6JRWK=
Ca-Ski M{frT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DJXmlEPTB;MD60NFUzPCEQvF2= NWfWVpptW0GQR1XS
SW13 M1O5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwNEC2NlYh|ryP NHOzTXlUSU6JRWK=
NCI-H1437 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwNEC4NFUh|ryP M4nFWXNCVkeHUh?=
U-118-MG M{Gzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS3[oZKSzVyPUCuOFA6ODRizszN MWTTRW5ITVJ?
NCI-H1734 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\nSXkxUUN3ME2wMlQzODF|IN88US=> MVjTRW5ITVJ?
HDLM-2 M2O5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDWTWM2OD1yLkSyNFM{KM7:TR?= NVrXSmJ4W0GQR1XS
AU565 NFHkW|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXWZo9lUUN3ME2wMlQzPDZ6IN88US=> MkjEV2FPT0WU
FADU M1Lh[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTuSW1KSzVyPUCuOFI3PDlizszN MXnTRW5ITVJ?
OS-RC-2 MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj0dnJRUUN3ME2wMlQ{ODh|IN88US=> NEi3N2ZUSU6JRWK=
CAMA-1 NHvrSWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwNEO2NlYh|ryP NEnZPWpUSU6JRWK=
MONO-MAC-6 NHmzUotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3NcnBKSzVyPUCuOFM5PDlizszN NYXQ[mtOW0GQR1XS
LB831-BLC M3e2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HuRmlEPTB;MD60OFM4OSEQvF2= NUjDNJAzW0GQR1XS
SW982 M{HyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXiS4NCUUN3ME2wMlQ1PTJ6IN88US=> NUjzU5c2W0GQR1XS
SCC-3 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwNES1O|kh|ryP MUfTRW5ITVJ?
C32 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwNEWyNlkh|ryP NXHlRllIW0GQR1XS
BFTC-909 NFu3[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2KyVWlEPTB;MD60OVI6QSEQvF2= NFzkVG5USU6JRWK=
MEG-01 M3rPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPLTWM2OD1yLkS1N|c{KM7:TR?= MWjTRW5ITVJ?
M14 NHnVSFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzRe2tZUUN3ME2wMlQ2QTd7IN88US=> NWn4[5pCW0GQR1XS
MPP-89 NXjtUWVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;0TWM2OD1yLkS2NlU3KM7:TR?= NUPxcXM1W0GQR1XS
HCC1937 MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnG0TWM2OD1yLkS2N|g1KM7:TR?= MWjTRW5ITVJ?
SW837 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfCO3pKSzVyPUCuOFY4OjJizszN M{TjdXNCVkeHUh?=
DU-145 NXrDO5czT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT1VlBqUUN3ME2wMlQ3PzJ7IN88US=> NYX3Z|lUW0GQR1XS
LB996-RCC M2\vfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnIeZVKSzVyPUCuOFcxPTRizszN MYPTRW5ITVJ?
C8166 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe4TppnUUN3ME2wMlQ4PCEQvF2= MUHTRW5ITVJ?
MOLT-4 NEX2[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;LVYlKSzVyPUCuOFc4OzRizszN MoPRV2FPT0WU
DMS-53 MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnKeoZIUUN3ME2wMlQ4QDB7IN88US=> M2L2TXNCVkeHUh?=
TE-5 MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjZeGt6UUN3ME2wMlQ5OzB3IN88US=> NVPOc3FtW0GQR1XS
KYSE-520 M3O4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljSTWM2OD1yLkS4N|Q{KM7:TR?= NVrpfm9EW0GQR1XS
Detroit562 M3z6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf4ToVVUUN3ME2wMlQ5QDZizszN NUXPNmVYW0GQR1XS
SIMA MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHDNopKSzVyPUCuOFk1OTdizszN M3fnUnNCVkeHUh?=
NCI-H1651 M2f6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnTenZKSzVyPUCuOFk3PyEQvF2= NI\leHhUSU6JRWK=
HCC1599 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojmTWM2OD1yLkS5PVU2KM7:TR?= M3LK[XNCVkeHUh?=
ABC-1 NF;uOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwNUC0PVYh|ryP MYnTRW5ITVJ?
CAL-33 Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFq4XWFKSzVyPUCuOVA5PDRizszN MWPTRW5ITVJ?
OPM-2 M174T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwNUC5N|ch|ryP M2i1U3NCVkeHUh?=
RPMI-7951 MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwNUC5OVch|ryP NXHxfFgzW0GQR1XS
HT-1080 M3jmV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPjZXA3UUN3ME2wMlUyOTF7IN88US=> MmPQV2FPT0WU
LC4-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DGUGlEPTB;MD61NVQxOyEQvF2= MYLTRW5ITVJ?
OVCAR-3 M{HkVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\BS5lyUUN3ME2wMlUyPTdizszN MnW0V2FPT0WU
CAPAN-1 NXy5dXJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XoRWlEPTB;MD61NlI5QCEQvF2= NIDRRZZUSU6JRWK=
SK-OV-3 MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Px[GlEPTB;MD61NlQ{PCEQvF2= NVv4UoNXW0GQR1XS
HuP-T3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDZTWM2OD1yLkWyPFI4KM7:TR?= NVr0clI{W0GQR1XS
NCI-H838 NX63XIJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwNUK4OFkh|ryP MV3TRW5ITVJ?
K5 M3fNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHrRoxKSzVyPUCuOVMzODFizszN M1jKfnNCVkeHUh?=
CAL-72 M3X0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHTXJRKSzVyPUCuOVM{QDdizszN MX7TRW5ITVJ?
NH-12 M3fYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq3RVF7UUN3ME2wMlU{QTV7IN88US=> NHnCPIZUSU6JRWK=
SNB75 M1LaN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jjdmlEPTB;MD61OVc{KM7:TR?= NEj2WZNUSU6JRWK=
BPH-1 NH7RT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHKe5NKSzVyPUCuOVY{PDRizszN NVfSRZNOW0GQR1XS
NOMO-1 MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PDSGlEPTB;MD61OlM4OiEQvF2= NVXyU4tlW0GQR1XS
G-402 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnCdIRtUUN3ME2wMlU3PDl7IN88US=> MXHTRW5ITVJ?
NCI-H2052 M2GyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwNU[3OFEh|ryP MVrTRW5ITVJ?
RCM-1 NGPKS|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHRTWM2OD1yLkW3NVY3KM7:TR?= NXrv[VVzW0GQR1XS
COR-L279 NUTJXIdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrHTWM2OD1yLkW3NVg2KM7:TR?= MojrV2FPT0WU
A253 M1[xZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjXWo45UUN3ME2wMlU4PTJ3IN88US=> NGftOIJUSU6JRWK=
SK-MM-2 M1rhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXoTWM2OD1yLkW3Olc6KM7:TR?= M1vnfXNCVkeHUh?=
NCI-H1703 M4XWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LJfWlEPTB;MD61PVQzPyEQvF2= NWr6Oml7W0GQR1XS
UACC-257 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwNUm0PFch|ryP M4P6fXNCVkeHUh?=
KALS-1 M2fsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jSfmlEPTB;MD62NFAyOSEQvF2= MX\TRW5ITVJ?
ES5 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XRcmlEPTB;MD62NFQ5KM7:TR?= MXvTRW5ITVJ?
MHH-CALL-2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;ZTWM2OD1yLk[wPFg5KM7:TR?= MWnTRW5ITVJ?
ChaGo-K-1 NGLkNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnIeIlKSzVyPUCuOlEzOjlizszN NHTjNoVUSU6JRWK=
TGBC1TKB NGToblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlu3TWM2OD1yLk[xPVgh|ryP NYTwdmpIW0GQR1XS
KU-19-19 Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnz1TWM2OD1yLk[0OVg3KM7:TR?= MkPBV2FPT0WU
COLO-684 NGHSUVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwNkW2NVEh|ryP MnnBV2FPT0WU
LS-1034 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonnTWM2OD1yLk[1PFE6KM7:TR?= NEjZcopUSU6JRWK=
RT-112 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFviOlBKSzVyPUCuOlY2QDdizszN M2nFenNCVkeHUh?=
Capan-2 MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnqeYlKSzVyPUCuOlY3OjJizszN MYjTRW5ITVJ?
HSC-4 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3L1[mlEPTB;MD62OlY6QCEQvF2= NYfFfJhEW0GQR1XS
COLO-824 NHfhSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXf1e3pUUUN3ME2wMlY4QDJ|IN88US=> NX;aNY16W0GQR1XS
NCI-H2170 NHLUdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\hWoVnUUN3ME2wMlY5OjV6IN88US=> MXTTRW5ITVJ?
GDM-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTwTWM2OD1yLk[4OFk1KM7:TR?= NEK2W4pUSU6JRWK=
KP-4 Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwNkm1O|Mh|ryP MnfCV2FPT0WU
VA-ES-BJ MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfSTGdKSzVyPUCuOlk6QDZizszN MYfTRW5ITVJ?
KM-H2 Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwN{CwPVEh|ryP MmjDV2FPT0WU
HH MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwN{C2OlIh|ryP MknsV2FPT0WU
DK-MG NV7FTGZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DjWmlEPTB;MD63NVAyPiEQvF2= MkP5V2FPT0WU
VM-CUB-1 MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjmT4hKSzVyPUCuO|EzPTlizszN NHTrdmpUSU6JRWK=
COLO-829 NGCwTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmn2TWM2OD1yLkexPVg2KM7:TR?= MlzwV2FPT0WU
OMC-1 NU\ocVcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoO5TWM2OD1yLkeyNVA1KM7:TR?= NVznVlhnW0GQR1XS
NB12 NFjjW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;JRmlEPTB;MD63NlUxPCEQvF2= MnGzV2FPT0WU
NCI-H28 M3\RdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljOTWM2OD1yLke0NFg{KM7:TR?= MkXLV2FPT0WU
A673 M2izeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:zRWlEPTB;MD63OVE4PyEQvF2= NGDzOIlUSU6JRWK=
LB2241-RCC NYDBd5hST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwN{[wPFch|ryP NX3UbIViW0GQR1XS
CCRF-CEM MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjEbppKSzVyPUCuO|cxPTJizszN MlvaV2FPT0WU
NCI-H510A M1G5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vaPWlEPTB;MD63O|E5PiEQvF2= NGHz[GtUSU6JRWK=
SW48 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkSwTWM2OD1yLke3N|M{KM7:TR?= NFW1XFBUSU6JRWK=
NCI-H2081 NYrkXWZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHDVXRKSzVyPUCuO|gyPDdizszN M1;LN3NCVkeHUh?=
RMG-I NHzqOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1f4W2lEPTB;MD63PFIyOiEQvF2= MlLxV2FPT0WU
LU-99A MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr3TWM2OD1yLke4OFE{KM7:TR?= NYX2dWVMW0GQR1XS
KP-N-YS Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\UbXZmUUN3ME2wMlc5QTJzIN88US=> MoTrV2FPT0WU
MDA-MB-231 M135TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwOECxN|Eh|ryP MmLQV2FPT0WU
U031 NVf1[WlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfiemNXUUN3ME2wMlgyPDJ|IN88US=> NXzkfZl7W0GQR1XS
EVSA-T NHnGRXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zVOWlEPTB;MD64NVY4OiEQvF2= MnTTV2FPT0WU
MDA-MB-157 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjEdIhJUUN3ME2wMlgzOjdzIN88US=> NVTH[mhuW0GQR1XS
EHEB NYX5[lVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jTfWlEPTB;MD64NlI4PiEQvF2= M2PWbHNCVkeHUh?=
KINGS-1 MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwOEK1OVUh|ryP M{DvU3NCVkeHUh?=
23132-87 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[yTWM2OD1yLkiyPFQ{KM7:TR?= M3\TNXNCVkeHUh?=
EFO-21 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvmXWZKSzVyPUCuPFQxQDlizszN MkC5V2FPT0WU
DOK MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLKOG9pUUN3ME2wMlg1QCEQvF2= M{\CTXNCVkeHUh?=
NCI-H2171 NUTueodRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXwTWM2OD1yLki0PVYh|ryP MYjTRW5ITVJ?
NCI-SNU-5 Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInhT2RKSzVyPUCuPFU2PyEQvF2= NIK0eHdUSU6JRWK=
SK-N-DZ MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHiSVlKSzVyPUCuPFU6PDNizszN M1rIbXNCVkeHUh?=
SNU-C2B MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPaTWM2OD1yLki2PFAyKM7:TR?= MoHLV2FPT0WU
CP66-MEL MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwOEexNUDPxE1? M{\KNHNCVkeHUh?=
SN12C M2nWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{OwdGlEPTB;MD64PFY{PyEQvF2= MV;TRW5ITVJ?
A172 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v6c2lEPTB;MD64PFY6QCEQvF2= MYTTRW5ITVJ?
NCI-H2347 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwOEi3OVMh|ryP M4rlSHNCVkeHUh?=
NCI-H2228 MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPTSpBKSzVyPUCuPFk{OzlizszN MlH3V2FPT0WU
SNU-387 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj6TWM2OD1yLkmwNlY1KM7:TR?= NHHHdWdUSU6JRWK=
SK-MEL-24 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfHVnhjUUN3ME2wMlkyOzR2IN88US=> M1TWVHNCVkeHUh?=
MDA-MB-468 MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS2TWM2OD1yLkmxO|Mh|ryP NYT6SYdVW0GQR1XS
NCI-H1694 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\ZTWM2OD1yLkmxPFc3KM7:TR?= MY\TRW5ITVJ?
CCF-STTG1 M4XmWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG4R3NKSzVyPUCuPVI3OzdizszN NEH5fZJUSU6JRWK=
K052 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XCc2lEPTB;MD65OFA1PyEQvF2= M{DN[nNCVkeHUh?=
NCI-H446 MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD4e3hNUUN3ME2wMlk2ODFizszN Ml7TV2FPT0WU
MFE-280 NEfZZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwOU[yPVEh|ryP NGH6XY9USU6JRWK=
KU812 Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf3W2tvUUN3ME2wMlk6Ozh7IN88US=> MW\TRW5ITVJ?
MDA-MB-361 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHyycZFKSzVyPUCuPVk4PzdizszN NXzNb2lMW0GQR1XS
Raji M3:y[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XxT2lEPTB;MT6wNlI3PyEQvF2= MXnTRW5ITVJ?
TE-6 NXzjeY14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X3PWlEPTB;MT6wN|U3PiEQvF2= NFnoWnNUSU6JRWK=
CAL-148 M4XXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3YcmNMUUN3ME2xMlA1PDR|IN88US=> NX;J[YhkW0GQR1XS
NCI-H1963 NYOwbZNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHE[HdRUUN3ME2xMlA1PTV|IN88US=> M3XtZ3NCVkeHUh?=
SK-N-AS NUnt[XFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYGz[GZ2UUN3ME2xMlA1Pjh3IN88US=> NEGybJFUSU6JRWK=
RERF-LC-MS NXrhbG5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jHZWlEPTB;MT6wOlM1QSEQvF2= NHLu[3VUSU6JRWK=
BEN NXPI[WdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTsTWM2OD1zLkC3NVM4KM7:TR?= NXXLepBlW0GQR1XS
CAS-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTFwMEmxNlMh|ryP M1XJeHNCVkeHUh?=
SW780 NHW0NohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2WwZWlEPTB;MT6wPVE5OSEQvF2= NYDjTYN3W0GQR1XS
LU-65 NUSydow3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HiVmlEPTB;MT6wPVQyKM7:TR?= MXLTRW5ITVJ?
D-283MED MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPjXXZKSzVyPUGuNVIzPzJizszN M1Hs[HNCVkeHUh?=
HCC2157 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTFwMUO2OFIh|ryP NYTXWVUxW0GQR1XS
RCC10RGB M2[2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHt[ZM6UUN3ME2xMlE1ODB4IN88US=> Mn;NV2FPT0WU
PLC-PRF-5 NE\SOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;Jb|NKSzVyPUGuNVUzOjlizszN MUfTRW5ITVJ?
H4 NYLU[HIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M132XmlEPTB;MT6xOVQ{QSEQvF2= NIWxNnJUSU6JRWK=
TUR NEPtbJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLuTWM2OD1zLkG1O|UzKM7:TR?= NYf1cJlwW0GQR1XS
NCI-H2141 Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPYTWM2OD1zLkG4PVQ3KM7:TR?= MoXPV2FPT0WU
PFSK-1 M4[2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq4TGFTUUN3ME2xMlIxPTN{IN88US=> MXjTRW5ITVJ?
SK-MEL-28 NWC3Nm06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPWWVd2UUN3ME2xMlI{OjJzIN88US=> MoLiV2FPT0WU
SCC-9 MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXtTWM2OD1zLkKzOlY2KM7:TR?= MoCyV2FPT0WU
T47D NFvCdVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXXNZVKSzVyPUGuNlM3QTZizszN MXfTRW5ITVJ?
TCCSUP M2jVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUe4SG45UUN3ME2xMlI2ODJ7IN88US=> MYjTRW5ITVJ?
SU-DHL-1 NF:0eVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTFwMkWxNVgh|ryP MVLTRW5ITVJ?
HL-60 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoGzTWM2OD1zLkK1OVg5KM7:TR?= M3fIT3NCVkeHUh?=
NCI-H1436 NHjlOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDUNHFqUUN3ME2xMlI3OTR7IN88US=> MXrTRW5ITVJ?
DMS-114 M17WcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nObWlEPTB;MT6yOlY{OiEQvF2= Mkf0V2FPT0WU
BOKU NXrvZmg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf4TWM2OD1zLkK4NFk2KM7:TR?= M1jJVXNCVkeHUh?=
MS-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFwMkmwOlkh|ryP NXfF[mVJW0GQR1XS
NCI-H661 NWraephvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTFwM{C0O|gh|ryP M1zqWXNCVkeHUh?=
HT-3 NFnpcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnWTWM2OD1zLkOwOVI6KM7:TR?= NGLYZ|ZUSU6JRWK=
CAL-54 NW\2NolQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHBNWlKSzVyPUGuN|A4OjVizszN MmW4V2FPT0WU
SW1463 NYPMSoxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPxPYxDUUN3ME2xMlMyQDd{IN88US=> M4Czb3NCVkeHUh?=
COLO-668 NUmwdlJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDve4dKSzVyPUGuN|MxPTZizszN MWjTRW5ITVJ?
PANC-08-13 M2TnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTFwM{O4NFMh|ryP M3f3UXNCVkeHUh?=
BB49-HNC NWPleJduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlSzTWM2OD1zLkO0NFEh|ryP M32xVHNCVkeHUh?=
M059J MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTFwM{W4N|Ih|ryP MmPxV2FPT0WU
NCCIT NIDDNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T3ZWlEPTB;MT6zO|k5QCEQvF2= MnG5V2FPT0WU
LN-405 NHLTVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHvUFVKSzVyPUGuN|kzPjRizszN Mn7mV2FPT0WU
UMC-11 M2\0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{P1OWlEPTB;MT6zPVk6PiEQvF2= Mo[zV2FPT0WU
NB5 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDKS|lKSzVyPUGuOFEzOjdizszN NYjENFZQW0GQR1XS
TE-441-T M1yzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\FXYNKSzVyPUGuOFI5OTdizszN MVnTRW5ITVJ?
ME-180 M3PJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPUOIdiUUN3ME2xMlQ1Ozl{IN88US=> MVjTRW5ITVJ?
HCC70 M3r1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TWSGlEPTB;MT60OlA6PiEQvF2= M4nVZXNCVkeHUh?=
no-10 MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFwNE[xPFEh|ryP MlHBV2FPT0WU
JEG-3 NI\qd4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfITWM2OD1zLkWwNVMzKM7:TR?= NGLLNZhUSU6JRWK=
no-11 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL2SllKSzVyPUGuOVA5QDJizszN NYL2[XhzW0GQR1XS
CHP-126 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTFwNU[2PVEh|ryP MUPTRW5ITVJ?
EGI-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13Ee2lEPTB;MT61PFAzPSEQvF2= NHrzNoVUSU6JRWK=
D-392MG NEXOZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfsTWM2OD1zLkW5OlMh|ryP MYHTRW5ITVJ?
RT4 MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonwTWM2OD1zLkW5OlM4KM7:TR?= MW\TRW5ITVJ?
A204 NWLCWINTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFwNUm4NFEh|ryP MmHEV2FPT0WU
NCI-H1304 NE\sb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfoTWM2OD1zLk[zOVkyKM7:TR?= NFzsdnZUSU6JRWK=
Becker M1rEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTFwNkSyOFEh|ryP NVGyc20xW0GQR1XS
OE19 NXK5RXBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFwNkW1NVgh|ryP MXzTRW5ITVJ?
EKVX M1:2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPYb|lKSzVyPUGuOlU3OThizszN MVXTRW5ITVJ?
KLE MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zoSGlEPTB;MT62OVcyPCEQvF2= MlXyV2FPT0WU
K-562 NHWyfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fuTmlEPTB;MT62O|A{PyEQvF2= M4\EOnNCVkeHUh?=
MDA-MB-175-VII NGL0ZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MliwTWM2OD1zLk[4PVk4KM7:TR?= MnfrV2FPT0WU
NCI-H716 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17vc2lEPTB;MT62PVMxPCEQvF2= NWfY[FJwW0GQR1XS
Caov-3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHMTWM2OD1zLk[5OFE{KM7:TR?= NV76fI1ZW0GQR1XS
HCC1187 Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jyNmlEPTB;MT63NFU1PSEQvF2= NIHlV|dUSU6JRWK=
CAKI-1 NV74dXJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\hTWM2OD1zLkeyNlkzKM7:TR?= NV6zOZZYW0GQR1XS
MOLT-16 MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\lXlNKSzVyPUGuO|M{ODdizszN Mn3mV2FPT0WU
PC-3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnITWM2OD1zLke1NFgh|ryP NWXReo5OW0GQR1XS
DV-90 NUXFNIdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfpTWM2OD1zLke1OVg2KM7:TR?= NFjmbIdUSU6JRWK=
RXF393 NVzTboNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrEPW9KSzVyPUGuO|czQTRizszN NXnyNJRnW0GQR1XS
SK-NEP-1 NIfabWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV33NWs2UUN3ME2xMlgzOzN7IN88US=> MnrnV2FPT0WU
HCC1419 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS4TWM2OD1zLkiyOlkzKM7:TR?= MV;TRW5ITVJ?
BV-173 MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfKTWM2OD1zLkiyPVk2KM7:TR?= Mn3mV2FPT0WU
MKN7 M1js[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fhT2lEPTB;MT64PVIzKM7:TR?= NVKxcYJVW0GQR1XS
LAN-6 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHlZlJxUUN3ME2xMlg6PTV|IN88US=> NEH1UoxUSU6JRWK=
Mo-T MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HoUmlEPTB;MT65NFA{QSEQvF2= MkOyV2FPT0WU
HCC1395 Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD4TWM2OD1zLkmyPFY{KM7:TR?= NGfLblFUSU6JRWK=
HC-1 M3y1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWraSG1rUUN3ME2xMlk{PDdizszN MnTXV2FPT0WU
HPAF-II M37xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkToTWM2OD1zLkm0OFE5KM7:TR?= MlLVV2FPT0WU
CPC-N MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTFwOUiwNFIh|ryP NEPCTXNUSU6JRWK=
MKN45 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTFwOUmxNVkh|ryP MUTTRW5ITVJ?
NCI-H1693 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\temw2UUN3ME2yMlAxPDN|IN88US=> NFnGcIxUSU6JRWK=
SHP-77 NU\qWotIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJwMEC1N|Mh|ryP MXrTRW5ITVJ?
NCI-H1522 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnuxTWM2OD1{LkCxO|I1KM7:TR?= M2j6UXNCVkeHUh?=
SW1573 NG\QeIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfPVoxKSzVyPUKuNFIzKM7:TR?= NHXtfoNUSU6JRWK=
DBTRG-05MG Mn6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJwME[wPFch|ryP NI\i[3RUSU6JRWK=
SCC-4 NVu1[49iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWCwco1nUUN3ME2yMlE1OzFizszN MojtV2FPT0WU
DMS-153 MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjZR5NOUUN3ME2yMlE3PjZ6IN88US=> NXmzXohRW0GQR1XS
MDA-MB-415 NEf1VllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLIVGV{UUN3ME2yMlE4PTJizszN M2TFeXNCVkeHUh?=
NCI-H2126 NIr3bmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vmW2lEPTB;Mj6yNlg5QCEQvF2= Mk\pV2FPT0WU
MDA-MB-453 M3PqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXGTWM2OD1{LkKzN|Ih|ryP NWG1Zog1W0GQR1XS
U-87-MG NUfNeXlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPp[Zg{UUN3ME2yMlI5PTl{IN88US=> MX7TRW5ITVJ?
LNCaP-Clone-FGC NVjvS2FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIW5OZZKSzVyPUKuN|AyODJizszN MoTLV2FPT0WU
NCI-H1581 MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{e5WGlEPTB;Mj6zNlExPSEQvF2= MXnTRW5ITVJ?
BC-3 NHjacmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PBPWlEPTB;Mj6zOlUxQSEQvF2= NXjRSno{W0GQR1XS
HCC38 M1vMeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJwM{i0OFch|ryP M1PoVXNCVkeHUh?=
HCC2218 M2LzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[zUmd1UUN3ME2yMlQxQDB7IN88US=> M4TM[nNCVkeHUh?=
RO82-W-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLOTWM2OD1{LkSxNlUh|ryP NHPseWpUSU6JRWK=
C2BBe1 Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rYeGlEPTB;Mj60NVU4QCEQvF2= NV3KN2xUW0GQR1XS
LAMA-84 Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M12xOWlEPTB;Mj61O|M3QCEQvF2= MWjTRW5ITVJ?
GMS-10 NGTh[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPYTWM2OD1{LkW3OlEyKM7:TR?= NV7TfmdsW0GQR1XS
GCT Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1u5TmlEPTB;Mj61PFY6PCEQvF2= MWrTRW5ITVJ?
SK-CO-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvJOWZKSzVyPUKuOlE3PiEQvF2= MljJV2FPT0WU
NCI-H526 NUi2cm4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkKxTWM2OD1{Lk[zOFUh|ryP MorvV2FPT0WU
SW1088 MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHReZpKSzVyPUKuO|c5OzlizszN MXHTRW5ITVJ?
HT55 Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TNTmlEPTB;Mj63PFY6PSEQvF2= MXLTRW5ITVJ?
NB10 MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjzTWM2OD1{LkixO|Q5KM7:TR?= MWLTRW5ITVJ?
UACC-893 M1nzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r3S2lEPTB;Mj64OVc1QSEQvF2= MXPTRW5ITVJ?
NCI-H1618 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HXZ2lEPTB;Mj64PFE2OyEQvF2= MXnTRW5ITVJ?
NCI-H1092 NEnIWIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTNwMEe4NVIh|ryP M3nZU3NCVkeHUh?=
SBC-1 M1n4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrVUWJKSzVyPUOuNFg2PTNizszN MULTRW5ITVJ?
NCI-H1623 M2K4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPwO5FKSzVyPUOuNFk{PCEQvF2= M2nMUHNCVkeHUh?=
SiHa NUjIe4QxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHGTWM2OD1|LkGxPVc4KM7:TR?= M2m2UnNCVkeHUh?=
D-263MG MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTNwMUS3PFgh|ryP MVPTRW5ITVJ?
NCI-H1573 MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTNwMUm2OFEh|ryP MUHTRW5ITVJ?
NCI-H82 MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[yVmlEPTB;Mz6zOFQ{QSEQvF2= MXPTRW5ITVJ?
NCI-H2196 M2\BPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnxR5FiUUN3ME2zMlM2ODB6IN88US=> M2PtPHNCVkeHUh?=
MFM-223 NWDye2dWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f3eWlEPTB;Mz6zO|M2OSEQvF2= NHfzdGlUSU6JRWK=
COLO-678 NEXnZ|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LvcWlEPTB;Mz6zPFE5PiEQvF2= NV:wUpRoW0GQR1XS
EW-3 M{jBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELTTZlKSzVyPUOuOFA6PSEQvF2= MXjTRW5ITVJ?
MHH-NB-11 NXXOZnVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPh[W1KSzVyPUOuOFQxPjlizszN NHu1Z4tUSU6JRWK=
EM-2 NEXjPJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvwPYQ6UUN3ME2zMlY{QThizszN NIfmTVRUSU6JRWK=
FTC-133 NILLPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXiXlBlUUN3ME2zMlY2PDV6IN88US=> M1XFe3NCVkeHUh?=
NCI-H209 NV7idIR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjJZ2RHUUN3ME2zMlY4PjV|IN88US=> NX\udnc{W0GQR1XS
TGBC24TKB Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnxVFJKSzVyPUOuOlg{PTVizszN M3TrWnNCVkeHUh?=
LC-1F M4jS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4P3ZWlEPTB;Mz63NVc3PCEQvF2= MV;TRW5ITVJ?
C-4-II MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\NXGlEPTB;Mz63OVY1OyEQvF2= NX\oWWNXW0GQR1XS
NCI-H1650 NIHVRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPvXJVKSzVyPUOuO|g1PTVizszN NHzOPXVUSU6JRWK=
JVM-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEK3OYZKSzVyPUOuPVM3OzlizszN NV\NUJZLW0GQR1XS
CaR-1 MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTNwOUe2NVch|ryP MX;TRW5ITVJ?
MDA-MB-134-VI MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGf0S2RKSzVyPUSuNFI6PTJizszN M{XmTnNCVkeHUh?=
NCI-H719 NULle|BET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTRwMUWzPFgh|ryP MWrTRW5ITVJ?
GOTO MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTRwMkm3NFUh|ryP NGDtPVdUSU6JRWK=
NCI-N87 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLQTWM2OD12LkO4PFIyKM7:TR?= MV3TRW5ITVJ?
NB6 NX7pXWw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHIc5NmUUN3ME20MlQzPTB7IN88US=> NUjvNnFJW0GQR1XS
DSH1 NH\M[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXwfHJKSzVyPUSuOFcyOTZizszN M4mwTnNCVkeHUh?=
BT-20 M2nwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[2eFRKSzVyPUSuOFkxODJizszN MoC2V2FPT0WU
NCI-H1882 NG\x[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTjTWM2OD12LkWwOVch|ryP MXPTRW5ITVJ?
WM-115 NXfmOnRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\mb4RKSzVyPUSuOVA5QDFizszN MV3TRW5ITVJ?
SKG-IIIa M1vKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\SRWlKSzVyPUSuOlc4PyEQvF2= NIfyOHhUSU6JRWK=
NCI-H69 M3frcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjpTWM2OD12LkewNlc2KM7:TR?= M4TCPHNCVkeHUh?=
MSTO-211H MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIO0dXJKSzVyPUSuPFM2PjVizszN MW\TRW5ITVJ?
Mewo MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTRwOU[zNVMh|ryP MVPTRW5ITVJ?
GI-ME-N M3O1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW2TWM2OD13LkCwOVA6KM7:TR?= MUfTRW5ITVJ?
T98G MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLwUFRKSzVyPUWuNFY2ODhizszN Mof5V2FPT0WU
ECC4 Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTVwMEmzO|Ih|ryP NEjB[HZUSU6JRWK=
EW-11 NWWx[WdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fVO2lEPTB;NT6xPFA6QSEQvF2= Ml\3V2FPT0WU
COLO-800 Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[xSWoxUUN3ME21MlE6OzR7IN88US=> NVzUO5J3W0GQR1XS
NCI-H1755 M3XhUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV33fpp6UUN3ME21MlI{ODJ5IN88US=> NY\Xd2w6W0GQR1XS
KMS-12-PE M2rCbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rnWWlEPTB;NT6zOVA5PSEQvF2= MkHvV2FPT0WU
HCC1954 MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LUVWlEPTB;NT64OVk4OSEQvF2= NWe5SWxnW0GQR1XS
NCI-H187 MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTVwOUK5PFkh|ryP NFXLb45USU6JRWK=
LU-165 M3zWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmq0TWM2OD13Lkm5NFAzKM7:TR?= NFz4c2dUSU6JRWK=
YAPC Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HoXWlEPTB;NT65PVA3QCEQvF2= MWnTRW5ITVJ?
LU-139 NFm3Z3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37VVGlEPTB;Nj6wPFM3QCEQvF2= NXHxfIdpW0GQR1XS
D-502MG MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTZwM{KwOFch|ryP M2jmcHNCVkeHUh?=
IST-SL1 NUTwXXNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTQTWM2OD14LkWzPVQ5KM7:TR?= NGLIVHpUSU6JRWK=
DG-75 NELjZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnnN4kzUUN3ME22Mlg5Pzh4IN88US=> NFvaS4lUSU6JRWK=
NCI-H1155 NGiy[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTZwOUW1PFEh|ryP MmXvV2FPT0WU
EFE-184 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXYdolKSzVyPUeuN|E3QTVizszN NHfKWoJUSU6JRWK=
AsPC-1 NEPhT|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljqTWM2OD15LkS4PFA4KM7:TR?= MlPOV2FPT0WU
SW948 MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTdwNUizPVUh|ryP MoTkV2FPT0WU
NCI-H524 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnpbFdKSzVyPUmuOVg3OjhizszN NHvmb3hUSU6JRWK=
KOSC-2 NHnzUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTlwNkK4N|Qh|ryP Ml3lV2FPT0WU
T-24 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTlwOUS0NVUh|ryP NVvZ[mQ{W0GQR1XS
NCI-H748 M4PaPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TmVmlEPTB;MUCuOlM6PyEQvF2= NXHD[IJHW0GQR1XS
NCI-H23 NYjZfpR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\nWmlKSzVyPUGwMlY1PDJizszN NW\OVI9YW0GQR1XS
UACC-812 NX7LPXh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID3PVJKSzVyPUGxMlcyPyEQvF2= M{jIeHNCVkeHUh?=
SCLC-21H MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLmNG9bUUN3ME2xNk4yPTVzIN88US=> NELubGNUSU6JRWK=
NCI-SNU-16 MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF|LkGyOVgh|ryP M4jHS3NCVkeHUh?=
HD-MY-Z MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;TfnJKSzVyPUG0MlY{PjNizszN Mn7nV2FPT0WU
SK-N-FI NG\GNmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjV[mhKSzVyPUG0Mlg6OTJizszN NEDaUpZUSU6JRWK=
LB647-SCLC M3XXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[xTWM2OD1zNT63NVk2KM7:TR?= M2fzWHNCVkeHUh?=
NCI-H345 M2XETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTF5LkO0N{DPxE1? M1PkcXNCVkeHUh?=
NCI-H1563 NXjrWWpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUWwcWlPUUN3ME2xPE44PjBzIN88US=> NH7OS21USU6JRWK=
RL NITEU5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTJzLkK2OVYh|ryP MXvTRW5ITVJ?
KY821 MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\nUGlEPTB;MkKuNFU2OyEQvF2= NUC1XXpZW0GQR1XS
JVM-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\kTWM2OD1{NT6wOFE{KM7:TR?= NH;YeIFUSU6JRWK=
NCI-H1793 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXTfWdKSzVyPUK4MlU1QTlizszN MUXTRW5ITVJ?
LU-134-A MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HZSmlEPTB;M{CuNlA{PyEQvF2= NWXp[|lCW0GQR1XS
NCI-H1395 NYX4RpRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7vVHhRUUN3ME2zNk4zPDNzIN88US=> MXXTRW5ITVJ?
NCI-H1993 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;qc2lEPTB;M{KuPFIyQCEQvF2= NYrjdFJyW0GQR1XS
P31-FUJ Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofFTWM2OD1|Mz60PFk6KM7:TR?= NEXKRmtUSU6JRWK=
LS-513 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnDR3VKSzVyPUO1Mlg5PzlizszN MnuxV2FPT0WU
SK-MEL-1 M{LnZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M360OWlEPTB;NECuN|Q6QSEQvF2= MknvV2FPT0WU
SW684 MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTR|Lkm2OlEh|ryP MonYV2FPT0WU
COR-L88 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPnclMyUUN3ME20OE4xPjZ3IN88US=> NV\YPYYyW0GQR1XS
NCI-H889 M3zidWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLtTWM2OD12NT6wNFg4KM7:TR?= MkfuV2FPT0WU
TALL-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjYSWdsUUN3ME20Ok4yOTl7IN88US=> MV;TRW5ITVJ?
KARPAS-299 NWPGRXN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf0TWM2OD12Nz6xPVk{KM7:TR?= NY\QOZFiW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. [1]

Protocol

Kinase Assay:[1]
+ Expand

Bcl-2 Binding affinity calculation:

A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. [4] As a control in determining the reliability of the calculation, predicted binding affinities Ki) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.
Cell Research:[2]
+ Expand
  • Cell lines: Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs)
  • Concentrations: ~10 μM
  • Incubation Time: 48-72 hours
  • Method: Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 104 per well for HMCLs or 5~10 × 103 for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used.
  • Formulation: Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 m
  • Dosages: 0.0313, 0.25, 0.5 and 2 mg/kg
  • Administration: Administered intravenously (tail vein) once a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 83 mg/mL (200.73 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 413.49
Formula

C20H19N3O.CH4O3S

CAS No. 803712-79-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01563601 Withdrawn Extensive-stage Small Cell Lung Cancer Cephalon|Teva Pharmaceutical Industries August 2012 Phase 3
NCT01238146 Withdrawn Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma National Cancer Institute (NCI) October 2010 Phase 1|Phase 2
NCT01150656 Completed Leukemia Children''s Oncology Group|National Cancer Institute (NCI) June 2010 --
NCT00933985 Terminated Acute Leukemias of Ambiguous Lineage|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Small Intestine Lymphoma|Unspecified Childhood Solid Tumor Protocol Specific National Cancer Institute (NCI) June 2009 Phase 1
NCT00521144 Completed Recurrent Small Cell Lung Cancer|Unspecified Adult Solid Tumor Protocol Specific National Cancer Institute (NCI) August 2007 Phase 1|Phase 2
NCT00427856 Completed Lymphoma Follicular Gemin X|Teva Pharmaceutical Industries March 2007 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) supplier | purchase Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) cost | Obatoclax Mesylate (GX15-070) manufacturer | order Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID